|
May 17
|
Insider Sale: Chief Legal Officer of Zai Lab Ltd (ZLAB) Sells Shares
|
|
May 16
|
Zai Lab Announces Participation in May and June Investor Conferences
|
|
May 14
|
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
|
|
May 13
|
BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
|
|
May 13
|
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
|
|
May 11
|
Zai Lab Limited (NASDAQ:ZLAB) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
|
|
May 10
|
Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
|
|
Apr 30
|
Zai Lab Limited's (NASDAQ:ZLAB) Profit Outlook
|
|
Apr 15
|
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
|
|
Apr 11
|
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
|
|
Apr 2
|
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
|
|
Apr 1
|
Shareholders in Zai Lab (NASDAQ:ZLAB) are in the red if they invested three years ago
|
|
Apr 1
|
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
|
|
Mar 27
|
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
|
|
Mar 20
|
Shhh! 7 Small-Cap Stocks That Can Double by 2025
|
|
Mar 19
|
Chief Legal Officer Edmondson Frazor Titus III Sells 10,000 Shares of Zai Lab Ltd (ZLAB)
|
|
Mar 13
|
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
|
|
Mar 6
|
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
|
|
Mar 6
|
Zai Lab Announces Participation in March Investor Conference
|